Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.49 |
| ▸ | PRKDC | P78527 | 5/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
| ▸ | HCK | P08631 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | MTOR | P42345 | 4/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.44 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966043 | 1.00 | IGF1R (0.53) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2967439 | 1.00 | IGF1R (0.53) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2959607 | 0.94 | IGF1R (0.54) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2956132 | 0.94 | IGF1R (0.54) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2956130 | 0.94 | IGF1R (0.54) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2960030 | 0.91 | IGF1R (0.57) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2956089 | 0.90 | SRC (0.51) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2956066 | 0.90 | IGF1R (0.53) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2956065 | 0.90 | IGF1R (0.53) | IGF1REGFRERBB2PIK3CDPIK3CA | |
| SCHEMBL2958145 | 0.90 | IGF1R (0.53) | IGF1REGFRERBB2PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111629694-B | Fiber bundle reinforced biocomposite medical implant | 奥西西奥有限公司 | 2024-05-17 | — | — | CN | claimed |
| CN-116963718-A | Composition for ophthalmic care | 瑞比奥科技公司 | 2023-10-27 | — | — | CN | claimed |
| CN-111050677-B | Fiber reinforced biocomposite threaded implant | 奥西西奥有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-106687077-B | Anisotropic biocomposite, medical implant comprising anisotropic biocomposite, and method of treatment thereof | 奥西奥有限公司 | 2021-07-27 | — | — | CN | claimed |
| CN-107106210-B | Continuous fiber reinforced biocomposite medical implants | 奥西奥有限公司 | 2021-05-04 | — | — | CN | claimed |
| CN-112601560-A | Precision surface treated biocomposite, medical implant comprising same, and method of treating same | 奥西西奥有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-111629694-A | Fiber bundle reinforced biocomposite medical implant | 奥西西奥有限公司 | 2020-09-04 | — | — | CN | claimed |
| EP-1753708-B1 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2018-02-21 | — | — | EP | claimed |
| EP-1973917-B1 | PROTEIN KINASE INHIBITORS | ABBVIE INC (US) | 2015-06-10 | — | — | EP | claimed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | claimed |
| EP-1753708-A4 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | UNIV BRIGHAM YOUNG (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1753708-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | Brigham Young University (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2005069998-A2 | NOVEL SIRTUIN ACTIVATING COMPOUNDS AND METHODS FOR MAKING THE SAME | BRIGHAM YOUNG UNIVERSITY TECHNOLOGY TRANSFER OFFICE (US) | 2005-08-04 | — | — | WO | claimed |
| EP-0733087-B1 | CROSS-LINKING AGENTS FOR POLYMERS WITH ACID ANHYDRIDE GROUPS | ATOCHEM ELF SA (FR) | 2001-03-14 | — | — | EP | claimed |
| EP-0662106-B1 | SINGLE-COMPONENT THERMOSETTING MASSES, STORAGE STABLE AT ROOM TEMPERATURE, MADE OF ANHYDRIDE GROUP-CONTAINING POLYMERS AND POWDERY CROSS-LINKING AGENTS, PROCESS FOR PRODUCING THE SAME AND THEIR USE | CIBA GEIGY AG (CH) | 1997-08-27 | — | — | EP | claimed |
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-118320091-A | Compositions of caspase inhibitors and methods of use thereof | 香港大学 | 2024-07-12 | — | — | CN | disclosed |
| US-4159387-A | Squaric acid esters | CIBA-GEIGY CORPORATION (US) | 1979-06-26 | — | — | US | disclosed |
| US-4159387-A | Squaric acid esters | CIBA-GEIGY CORPORATION (US) | 1979-06-26 | — | — | US | disclosed |
| US-4137221-A | Heat-curable and solvent-soluble ester group-containing polymer compositions and process for their preparation | TEIJIN LIMITED (JP) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | HIF1A, HIF1AN, MYLK2 | IGF1R 1277/4885EGFR 4045/4885ERBB2 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.